Hospital Universitario La Paz-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  2. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2023

  1. AEEH «Consensus about detection and referral of hidden prevalent liver diseases»

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 3, pp. 236-247

  2. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  3. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19

    The Journal of infectious diseases, Vol. 222, Núm. 5, pp. 726-733

  3. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  4. Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis

    Clinical Infectious Diseases, Vol. 71, Núm. 10, pp. 2726-2729

  5. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients

    Liver International, Vol. 40, Núm. 9, pp. 2215-2227

  6. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2019

  1. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592

  2. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

  3. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

    The Lancet, Vol. 394, Núm. 10215, pp. 2184-2196

  4. Shadow cells in a cutaneous epidermoid cyst: searching for a polyposis syndrome

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 6, pp. 386-387

2018

  1. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

    The Lancet Gastroenterology and Hepatology, Vol. 3, Núm. 6, pp. 383-403

  2. Intestinal perforation secondary to intestinal diffuse large b-cell lymphoma in a patient with coeliac disease

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 8, pp. 503-504

2017

  1. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  2. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822